This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

As weight-loss injectables like Ozempic skyrocket in popularity, a new offshoot trend is starting to take hold: microdosing. But experts have concerns.

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics ' ( VKTX 0.32%) stock in ...

I t’s hard to overstate just how revolutionary the development of medications like Ozempic and Wegovy has been for managing type 2 diabetes and promoting weight loss. Far from b ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Novo Nordisk ... weight to the hypothesis that the GLP-1 may reduce craving for alcohol and nicotine via a similar mechanism to its ability to reduce food cravings and help people achieve weight loss.